Skip to main content

Table 2 Safety markers at baseline, week 4 and week 12 by group

From: Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers

  A20E10 (n = 48) A40 (n = 50) P value
ALT(U/L)
 Baseline 23.44 ± 15.36 19.90 ± 10.84 0.190
 Week 4 30.20 ± 14.52 27.51 ± 16.78 0.410
 Week 12 31.39 ± 19.38 28.39 ± 22.36 0.552
AST(U/L)
 Baseline 19.89 ± 5.99 17.80 ± 6.01 0.089
 Week 4 22.84 ± 5.69 21.24 ± 6.92 0.231
 Week 12 31.39 ± 19.38 28.39 ± 22.36 0.321
CK(U/L)
 Baseline 82.13 ± 35.11 107.60 ± 117.44 0.157
 Week 4 95.05 ± 35.58 100.86 ± 40.46 0.466
 Week 12 104.39 ± 48.86 115.60 ± 57.01 0.386
  1. Notes: A20E10 indicates the patients who received Atorvastatin 20 mg qn plus Ezetimibe 10 mg qd,A40 indicates the patients who received Atorvastatin 40 mg qn